Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA). It is designed to block the binding of opioids to the opioid receptors in the gastrointestinal tract without impacting the opioid receptors in the brain. Movantik was developed using Nektar Therapeutics’ oral small molecule polymer conjugate technology.
Movantik was previously approved in September 2014 as a Schedule CII controlled substance because it is structurally related to noroxymorphone, but the >Drug Enforcement Administration (DEA) removed it from the schedules of the Controlled Substances Act (CSA) in February 2014.
This removal was in response to a review of the available data that included scientific and medical evaluation and a recommendation from the Department of Health and Human Services (HHS).
Movantik is available in 12.5mg and 25mg dosage strengths.
For more information call (800) 236-9933 or visit movantik.com.
This article originally appeared on MPR